Skip to content
TrackPodcasts
technologyJan 26, 20266:19pending

AI in Drug Trials, Pfizer's Innovations, and NVIDIA's CoreWeave Partnership

About this episode

In this episode, Bob introduces the role of AI in drug development, particularly its impact on streamlining clinical trials. The discussion then shifts to Pfizer's recent innovations in AI, which have reportedly reduced the time to market for new drugs. Bob highlights Recursive's advancements in self-improving AI systems and their recent funding achievements. Attention is given to NVIDIA's collaboration and investment in CoreWeave's AI factories, which aim to bolster AI infrastructure. The episode concludes with closing remarks and an outlook on future developments in AI, emphasizing the importance of these advancements in shaping the industry.

Get every episode summarized

Each time The AI News Daily Brief publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

Hosts & guests

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

AI in Drug Trials, Pfizer's Innovations, and NVIDIA's CoreWeave Partnership

The AI News Daily Brief

0:00
6:19

More episodes

More from The AI News Daily Brief

View all episodes →